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LETTER
TO THE EDITORReumatismo, 2018; 70 (2): 117
Dear Editor,We read with interest the systematic 
review recently published by Muller et al. 
(1), in which the authors discuss the cur-
rent evidence concerning the incremen-
tal risk of underlying neoplastic diseases 
in patients with polymyalgia rheumatica 
(PMR). In their review, the authors ana-
lysed the results obtained in several cohort 
studies, including one by our group (2), 
where we reported an OR=5.1 (CI 95% 
2.9-8.9), significantly higher than in other 
papers. Based on these large differences, 
Muller et al. conclude that there is little ev-
idence of PMR as a true paraneoplastic dis-
ease but suggest caution when a diagnosis 
of PMR is made, since symptoms of can-
cer are difficult to differentiate from true 
PMR. Although their suggestion is worthy 
of endorsement, the reasoning behind it has 
some inescapable weaknesses. Firstly, the 
definition of what is a paraneoplastic con-
dition remains controversial. Secondly, in 
the papers they considered for their review 
the diagnosis of PMR was based on differ-
ent sets of criteria, outlining the difficulty 
of defining true PMR. Importantly, the 
follow-up period for linking PMR to can-
cer was different from one study to another, 
reflecting arbitrary limits rather than objec-
tive considerations, and so clearly impact-
ing on the strength of the association. In 
our paper, PMR was considered as poten-
tially cancer-associated when a patient was 
diagnosed with cancer within two years 
before and after PMR diagnosis. Other 
authors made different choices; for exam-
ple, in a paper published in 2014, Muller 
et al. excluded from their large, observa-
tional cohort all those PMR patients who 
had already received a diagnosis of cancer 
(3). They still found a significant associa-
tion with the risk of cancer, but obviously 
lower than in our cohort. This does not nec-
essarily mean that all the cancer-associated 
PMR cases observed in our study were 
actually paraneoplastic; however, it does 
testify that patients who receive a diagno-
sis of PMR are at higher risk for receiving 
or having recently received a diagnosis 
of cancer. Moreover, our study, although 
limited by a relatively small sample size, 
took advantage of a clinical follow-up of 2 
years, while the majority of studies dealing 
with the same issue are registry-based. This 
might have contributed to the differences in 
the observed results.
Taking together all these considerations, it 
is our opinion that the prevalence of para-
neoplastic PMR is generally underestimat-
ed. A properly tailored prospective cohort 
study is required to clarify better whether 
patients with PMR are at higher risk of 
cancer and, therefore, to decide which 
screening strategies, if any, are appropriate.
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